explore -WSS

explore

author：explore 2025-09-05 07:00:36 - browse：227

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Humana sues Biden admin over Medicare Advantage audit rule

Wikipedia

WSS

With competition flaring, obesity drug hits goal in liver disease study

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Medicare inequities exacerbate Puerto Rico’s health disparities

Ethical issues complicate the benefits of medical crowdfunding

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

leisure time

explore

focus

In age of alternative facts, a scholarly course on calling out crap

Dario to buy mental health app maker Twill in cash and stock deal

Psychedelics group wrestles with new pharma identity

NIH study of ME/CFS points to clear biological hallmarks

In Memoriam: Notable people who died in 2023

Illumina names Agilent executive as new CEO

Duchenne breakthrough therapy leaves behind pioneering families

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

The cancer drug shortage isn’t new — and neither are the solutions

Medicare inequities exacerbate Puerto Rico’s health disparities

explore

What drug price negotiations mean for Medicare Part D

Covid hospitalizations on the rise, Humana says

What American doctors can learn from their Israeli counterparts

NIH study of ME/CFS points to clear biological hallmarks

How to fix cancer clinical trials' diversity problem

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

focus

focus

Wikipedia

hotspot